Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ENZON, Inc. - New Chairman -- Ignore unavailable to you. Want to Upgrade?

To: ocerg who wrote (67)	3/19/1998 7:40:00 PM
From: ocerg	Read Replies (1) \| Respond to of 96

To follow up on yesterday's post, I talked with Enzon IR today. The feeling is that SGP is very pleased with the potential of PEG Intron A. Enzn feels that the motivation for PEG is the competitive advantage it offers over non-PEG formulations. Amgen for one is developing a drug to compete with Intron A. The PEG modified version seems to have decided advantages over its competitors. Bottom line, while the patent life extension was certainly a consideration in SGP's decision to go forward with its PEG development, the competitive leg up PEG Intron A seems to offer is the main focus. Enzon was given mention in SGP's annual report with regards to the PEG modified Intron A. It was also noted that a PEG formulation is in pre-clinical trials for oncology indications.